Atea Study Site
Lincoln, Nebraska, 68502, United States
NCT Number: NCT05004415
Mass balance study of AT-527 in Healthy Male Subjects.
Looking for future studies?
Notify Me19 year–55 year
Male
Interventional
Phase 1
Lincoln, Nebraska, 68502, United States
This is an open-label, single-dose study assessing the absorption, metabolism, excretion, and mass balance of [14C]-AT-527 in healthy adult male subjects.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Study participants will receive a single radiolabeled dose of 550 mg AT-527.
Time frame: Day 1 to Day 15
Total radioactivity recovery in urine and feces
Time frame: Day 1 to Day 15
Percent of radioactive dose excreted in urine and feces
Atea Pharmaceuticals, Inc.
Industry
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-AT-527 in Healthy Adult Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06911320
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orlando, Florida, United States
View Trial DetailsNCT07511400
Acute Pain, Common Cold
Vienna, State of Vienna, Austria
View Trial DetailsNCT07628465
Healthy Volunteer Study
Sfax, Tunisia
View Trial DetailsNCT07272889
Healthy Volunteer Study
Québec, Montreal, Canada
View Trial Details